Long term outcomes with emicizumab in hemophilia A without inhibitors result from HAVEN 3 and 4 studies - Johnny Mahlangu; Víctor Jimenez-Yuste; Giuliana Ventriglia; Markus Niggli; Simona Barlera; E et al (WILEY-BLACKWELL, 2024)